A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

drug protocol number
RPC01-3203
drug sponsor
Celgene
drug study
Ozanimod HCl
drug trial site
KAUH-J
drug status
Ongoing
drug phase